Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although statin therapy reduces cardiovascular risk, its relationship with the development of diabetes is controversial. The first study (West of Scotland Coronary Prevention Study [WOSCOPS]) that evaluated this association reported a small protective effect but used nonstandardized criteria for diabetes diagnosis. However, results from subsequent hypothesis-testing trials have been inconsistent. The aim of this meta-analysis is to evaluate the possible effect of statin therapy on incident diabetes. RESEARCH DESIGN AND METHODS: A systematic literature search for randomized statin trials that reported data on diabetes through February 2009 was conducted using specific search terms. In addition to the hypothesis-generating data from WOSCOPS, hypothesis-testing data were available from the Heart Protection Study (HPS), the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), and the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), together including 57,593 patients with mean follow-up of 3.9 years during which 2,082 incident diabetes cases accrued. Weighted averages were reported as risk ratios (RRs) with 95% CIs using a random-effects model. Statistical heterogeneity scores were assessed with the Q and I2 statistic. RESULTS: In the meta-analysis of the hypothesis-testing trials, we observed a small increase in diabetes risk (RR 1.13 [95% CI 1.03–1.23]) with no evidence of heterogeneity across trials. However, this estimate was attenuated and no longer significant when the hypothesis-generating trial WOSCOPS was included (1.06 [0.93–1.25]) and also resulted in significant heterogeneity (Q 11.8 [5 d.f.], P = 0.03, I2 = 57.7%). CONCLUSIONS: Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship of statin therapy to incident diabetes remains uncertain. Future statin trials should be designed to formally address this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (162,163), which may be limited to those with diabetes risk factors.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (156,157), which may be limited to those with diabetes risk factors and/or impaired glucose tolerance.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In primary prevention, however, among individuals with no previous cardiovascular events, its net benefit is more controversial (156,168).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk individuals with previous MI or stroke (secondary prevention) and is strongly recommended.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“In primary prevention, however, among patients with no previous cardiovascular events, its net bene fi t is more controversial (129,140).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [129]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“To assess heterogeneity across studies, we used the Cochran Q statistic based on the pooled RR by Mantel-Haenszel and measured inconsistency (I(2); the percentage of total variance across studies attributable to heterogeneity rather than chance) of treatment effects across trials (9).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“The summary RR and its 95% CI were estimated using the DerSimonian and Laird method for random effects (8).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Subsequent statin trials did not confirm this protective effect, and in the recent JUPITER a small but significant increase in physician-reported diabetes was reported among statin users compared with those taking placebo, although in the absence of any effect on glucose levels (6).”
ResultSelf-citationSever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citation(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 1×
“A few studies have suggested that statin use may result in an increase in A1C levels (2,17), although these effects have been quite small.”
BackgroundRosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844 · cited 1×
“(1) reported an inverse association between pravastatin use and diabetes incidence in the WOSCOPS (RR 0.”
Background
Research works printed but not linked: 1
- Sabatine, 2004, High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy (Abstract), Circulation, 110, S834
Cited by
Items 401–439 of 439
The Glycemic Consequences of Antihypertensive Medications
Barzilay, J. I., Whelton, P. K., & Davis, B. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_44 · Cited by 2
[Research progress in sperm mediated gene transfer technology].
Hao, X., Zhu, Z., Cao, M., Li, C., & Lin, Y. (2013) · PubMed
人間ドック・定期健診受診者における糖尿病新発症と糖尿病寛解に関連する因子の調査 -抗高脂血症内服薬治療は糖尿病の寛解に影響するか?-
順子, 石., & 惇, 阿. (2015) · doi:10.11320/ningendock.30.735
Multimorbidity, Management of COPD and Health Outcomes among Medicaid Beneficiaries
Ajmera, M. (2014) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.5039
Schofield, C. J. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Effect of statins on the risk of new cases of diabetes
Шалаев, С. В., & Мидхатовна, С. З. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-3-54-57
Giga, V. L., & Petrovic, M. T. (2017) · Glasnik Instituta za �titastu �lezdu i metabolizam · doi:10.5937/medgla1764018g
“A much more important adverse effect is increase in new cases of diabetes mellitus, that has been estimated to range from 9-13% of new cases of diabetes with prolonged statin treatment (15-17).”
BackgroundRoseman, M., Lexchin, J., & Turner, E. H. (2017)
Co wiadomo o diabetogennym działaniu statyn
Kłosiewicz−Latoszek, L., & Cybulska, B. (2013) · Via Medica Journals
Pravastatin: A First Generation HMG CoA Reductase Inhibitor ☆
Reagan, J. W. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.97874-7 · Cited by 2
Diabetes mellitus and heart diseases
Bayramova, A. (2018) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000031
Drugs for Treatment of Dyslipidemia Available in the USA
Streja, E., & Streja, D. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_13
Zhang, X., Gu, Y. H., Deng, H., Xu, Z. Q., Zhong, Z., Jin, H. M., & Yang, X. H. (2020) · Research Square · doi:10.21203/rs.3.rs-70758/v3
Statin use and the risk of new-onset diabetes mellitus: a retrospective cohort study
Alsafar, A., Albohamood, H., Alluwaym, I., Alzakari, M., Alobaidi, R., Alawadh, M., Joseph, R., & Cyrus, C. (2021) · International Journal of Medicine in Developing Countries · doi:10.24911/ijmdc.51-1609676604 · Cited by 1
STATINS DRUG USE AND DRUG-DRUG INTERACTIONS
N.Setiawati, M. C., Mutiarawati, C., Chasanah, U., & Fauziyyah, L. F. (2021) · JIFFK Jurnal Ilmu Farmasi dan Farmasi Klinik · doi:10.31942/jiffk.v17i2.4068
“In 2012, statins as a cholesterol-lowering drugs received a US Food and Drug Administration warning, regarding an increased risk of incident diabetes (Rajpathak et al., 2009).”
BackgroundRepurposing statin and L-glutamine: replenishing β-cells in hyperlipidemic T2D mouse modelPreprint
Palit, S., Patel, R., Parmar, N., Rathwa, N., Dalvi, N., Ramachandran, A., & Begum, R. (2021) · bioRxiv · doi:10.1101/2021.04.22.440866
“…showed those who are >60 years of age or are being treated with an intensive-dose of statin therapy have higher chances of developing new-our results (Rajpathak et al., 2009; Sattar et al., 2010; Preiss et al., 2011) clearly stating that effect of statin is largely based on the dosage recommended.”
BackgroundChowdhury, S. R. (2021) · Journal of Endocrinology and Thyroid Research · doi:10.19080/jetr.2020.05.555674 · Cited by 40
“Recent meta-analyses point to a relative increase in diabetes with prolonged statin use with this increased risk being attributed to the statin dose [22-24].”
BackgroundCurrent literature in diabetes
John Wiley & Sons, L. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1019 · Cited by 1
Zhang, X., Deng, H., Xu, Z. Q., Zhong, Z., Jin, H. M., & Yang, X. H. (2020) · Research Square · doi:10.21203/rs.3.rs-70758/v1
Zhang, X., Deng, H., Xu, Z. Q., Zhong, Z., Jin, H. M., & Yang, X. H. (2020) · Research Square · doi:10.21203/rs.3.rs-70758/v2
Selvasudha, N., Koumaravelou, K., & Sridurga Devi, N. (2017) · SM Analytical and Bioanalytical Techniques · doi:10.36876/smabt.1013s
Chongthammakun, V., & Krasuski, R. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000116
“Several clinical trials over the past decade have identified an increased risk of diabetes for statin users [4,5].”
BackgroundLinden, B. (2010) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2010.5.5.47895
The Impact of Age on Statin-Related Glycemia: A Propensity Score-Matched Cohort Study in Korea
Xu, S., Rha, S., Choi, B. G., & Seo, H. S. (2022) · Healthcare · doi:10.3390/healthcare10050777 · Cited by 1
“5 as a parameter of insulin resistance [15].”
BackgroundPrecision Medicine for Diabetes and Dyslipidemia
Alexander, E., Cristiano, E., & Miles, J. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_3
Links Between Glucose and Lipoproteins
Jenkins, A. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_3
Obad, A., Singh, R., Nasruddin, S., Holmes, E. R., & Rosenthal, M. (2023) · Healthcare · doi:10.3390/healthcare11152117 · Cited by 1
Tuquerres, D. A. C., Perez, P. N., Erazo, A. M. B., Figueroa, L., Fériz, K., & Casanova, M. (2023) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.2.9489
Schwartz, G. G., & Do, R. Q. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00039-6
Arefanian, H., Sindhu, S. T. A. K., Al‐Rashed, F., Alzaïd, F., Madhoun, A. S. A., Qaddoumi, M., Bahman, F., Williams, M. R., Albeloushi, S., Almansour, N., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1383448
Exploratory Approaches to Prevent Type 2 Diabetes
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407625.ch10
Hadgu, A., Yan, F., Effoe, V. S., & Mayberry, R. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.10.009
Yang, B., Yao, B., Zou, Q., Li, S., Yang, S., & Yang, M. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/3661739 · Cited by 1
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Choi, J. Y., Choi, C. U., Choi, B. G., Park, Y., Kang, D. O., Jang, W. Y., Kim, W., Na, J. O., Kim, J. W., Kim, E. J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13719390
Duan, J., Yu, W., Niu, Y., Li, J., & Xue, Z. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108509
Maideen, N. M. P., Jumale, A. H., Albasti, A. K., Kadir, D. A. A., Alkhawalda, M. Y., Shokr, A. F., & Canani, M. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x429107251202110301 · Cited by 1
Classification of Cardiovascular Disease Risk and Cardiovascular Disease Prevention in Women
Lewandowski, R., & Gracey, C. F. (2013) · Springer eBooks · doi:10.1007/978-1-4471-5517-1_2 · Cited by 1
Metadata
- Authors
- Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Cleveland Clinic (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Rajpathak, Swapnil N.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-10-01
- Volume
- 32
- Issue
- 10
- Pages
- 1924-1929
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2752935
- OpenAlex
- W2121535401
- Cited by
- 439
- References
- 21
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 20 · 2023: 15 · 2022: 19 · 2021: 19 · 2020: 16 · 2019: 34 · 2018: 21 · 2017: 28 · 2016: 27 · 2015: 45 · 2014: 41 · 2013: 50 · 2012: 44
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (5P60DK2054, P60DK020541)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin therapy, type 2 diabetes, incident diabetes risk, WOSCOPS, Heart Protection Study, ASCOT trial, JUPITER trial, CORONA trial, cardiovascular risk
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Risk Factors, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

